Base de dados : MEDLINE
Pesquisa : G07.690.773.968.511 [Categoria DeCS]
Referências encontradas : 2182 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 219 ir para página                         

  1 / 2182 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29345156
[Au] Autor:Svetel M; Tomic A; Kresojevic N; Kostic V
[Ad] Endereço:a Clinic of Neurology, Clinical Center of Serbia, Faculty of Medicine , University of Belgrade , Belgrade , Serbia.
[Ti] Título:Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson's disease.
[So] Source:Expert Opin Drug Metab Toxicol;14(3):353-360, 2018 Mar.
[Is] ISSN:1744-7607
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Opicapone (OPC) is a novel, potent, reversible, and purely peripheral third-generation COMT inhibitor, which provides an enhancement in levodopa (L-Dopa) availability. It represents adjunctive therapy for L-Dopa treated patients with PD and motor fluctuations. Areas covered: The purpose of this study was to evaluate pharmacokinetic of OPC for the treatment of PD. Expert commentary: Oral OPC exhibits linear, dose-dependent absorption. However, following concomitant ingestion of a high-fat, high-calorie meal, the maximum plasma concentration will be decreased. A once-daily bedtime administration of OPC 1 h after the last daily L-Dopa/AADCi, are considered to avoid any interaction during the L-Dopa absorption phase. There are no clinically relevant effects of age (in adults), renal impairment or race on the pharmacokinetics of OPC. OPC dose adjustment is not needed in patients with mild to moderate chronic hepatic impairment. Opicapone exhibits the lowest potential for cytotoxicity in comparison with other COMT inhibitors. It significantly decreases COMT activity, with half-life of COMT inhibition in human erythrocytes of 61.6 h and increases systemic exposure to L-Dopa. This provides an enhancement in L-Dopa availability that translates into clinical benefit for PD patients in terms of significant decrease of OFF periods and increase in ON-time without troublesome dyskinesia.
[Mh] Termos MeSH primário: Antiparkinsonianos/administração & dosagem
Oxidiazóis/administração & dosagem
Doença de Parkinson/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Animais
Antiparkinsonianos/efeitos adversos
Antiparkinsonianos/farmacocinética
Inibidores de Catecol O-Metiltransferase/administração & dosagem
Inibidores de Catecol O-Metiltransferase/farmacocinética
Relação Dose-Resposta a Droga
Quimioterapia Combinada
Interações Alimento-Droga
Meia-Vida
Seres Humanos
Levodopa/administração & dosagem
Levodopa/farmacocinética
Oxidiazóis/efeitos adversos
Oxidiazóis/farmacocinética
Doença de Parkinson/fisiopatologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antiparkinson Agents); 0 (Catechol O-Methyltransferase Inhibitors); 0 (Oxadiazoles); 46627O600J (Levodopa); Y5929UIJ5N (opicapone)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180119
[St] Status:MEDLINE
[do] DOI:10.1080/17425255.2018.1430138


  2 / 2182 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29220436
[Au] Autor:Ni Y; Jensen K; Kouskoumvekaki I; Panagiotou G
[Ad] Endereço:Systems Biology & Bioinformatics Group, School of Biological Sciences, The University of Hong Kong, Pokfulam Road, Hong Kong.
[Ti] Título:NutriChem 2.0: exploring the effect of plant-based foods on human health and drug efficacy.
[So] Source:Database (Oxford);2017, 2017 Jan 01.
[Is] ISSN:1758-0463
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Database URL: http://sbb.hku.hk/services/NutriChem-2.0/.
[Mh] Termos MeSH primário: Bases de Dados de Produtos Farmacêuticos
Bases de Dados de Proteínas
Interações Alimento-Droga
Plantas Comestíveis
[Mh] Termos MeSH secundário: Biologia Computacional
Mineração de Dados
Seres Humanos
Interface Usuário-Computador
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171209
[St] Status:MEDLINE
[do] DOI:10.1093/database/bax044


  3 / 2182 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28450226
[Au] Autor:Hara A; Endo S; Matsunaga T; El-Kabbani O; Miura T; Nishinaka T; Terada T
[Ad] Endereço:Faculty of Engineering, Gifu University, Gifu 501-1193, Japan.
[Ti] Título:Human carbonyl reductase 1 participating in intestinal first-pass drug metabolism is inhibited by fatty acids and acyl-CoAs.
[So] Source:Biochem Pharmacol;138:185-192, 2017 08 15.
[Is] ISSN:1873-2968
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Human carbonyl reductase 1 (CBR1), a member of the short-chain dehydrogenase/reductase (SDR) superfamily, reduces a variety of carbonyl compounds including endogenous isatin, prostaglandin E and 4-oxo-2-nonenal. It is also a major non-cytochrome P450 enzyme in the phase I metabolism of carbonyl-containing drugs, and is highly expressed in the intestine. In this study, we found that long-chain fatty acids and their CoA ester derivatives inhibit CBR1. Among saturated fatty acids, myristic, palmitic and stearic acids were inhibitory, and stearic acid was the most potent (IC 9µM). Unsaturated fatty acids (oleic, elaidic, γ-linolenic and docosahexaenoic acids) and acyl-CoAs (palmitoyl-, stearoyl- and oleoyl-CoAs) were more potent inhibitors (IC 1.0-2.5µM), and showed high inhibitory selectivity to CBR1 over its isozyme CBR3 and other SDR superfamily enzymes (DCXR and DHRS4) with CBR activity. The inhibition by these fatty acids and acyl-CoAs was competitive with respect to the substrate, showing the K values of 0.49-1.2µM. Site-directed mutagenesis of the substrate-binding residues of CBR1 suggested that the interactions between the fatty acyl chain and the enzyme's Met141 and Trp229 are important for the inhibitory selectivity. We also examined CBR1 inhibition by oleic acid in cellular levels: The fatty acid effectively inhibited CBR1-mediated 4-oxo-2-nonenal metabolism in colon cancer DLD1 cells and increased sensitivity to doxorubicin in the drug-resistant gastric cancer MKN45 cells that highly express CBR1. The results suggest a possible new food-drug interaction through inhibition of CBR1-mediated intestinal first-pass drug metabolism by dietary fatty acids.
[Mh] Termos MeSH primário: Acil Coenzima A/metabolismo
Oxirredutases do Álcool/antagonistas & inibidores
Ácidos Graxos não Esterificados/metabolismo
Mucosa Intestinal/enzimologia
[Mh] Termos MeSH secundário: Oxirredutases do Álcool/genética
Oxirredutases do Álcool/metabolismo
Sítios de Ligação
Ligação Competitiva
Linhagem Celular Tumoral
Resistência a Medicamentos Antineoplásicos
Interações Alimento-Droga
Seres Humanos
Mutação
Ácido Mirístico/metabolismo
Proteínas de Neoplasias/antagonistas & inibidores
Proteínas de Neoplasias/metabolismo
Oxirredutases/antagonistas & inibidores
Oxirredutases/genética
Oxirredutases/metabolismo
Ácido Palmítico/metabolismo
Palmitoil Coenzima A/metabolismo
Proteínas Recombinantes/química
Proteínas Recombinantes/metabolismo
Ácidos Esteáricos/metabolismo
Desidrogenase do Álcool de Açúcar/antagonistas & inibidores
Desidrogenase do Álcool de Açúcar/genética
Desidrogenase do Álcool de Açúcar/metabolismo
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Acyl Coenzyme A); 0 (Fatty Acids, Nonesterified); 0 (Neoplasm Proteins); 0 (Recombinant Proteins); 0 (Stearic Acids); 0I3V7S25AW (Myristic Acid); 1716-06-9 (oleoyl-coenzyme A); 1763-10-6 (Palmitoyl Coenzyme A); 2V16EO95H1 (Palmitic Acid); 362-66-3 (stearoyl-coenzyme A); 4ELV7Z65AP (stearic acid); EC 1.- (Oxidoreductases); EC 1.1.- (Alcohol Oxidoreductases); EC 1.1.- (Sugar Alcohol Dehydrogenases); EC 1.1.1.10 (L-xylulose reductase); EC 1.1.1.184 (CBR1 protein, human); EC 1.1.1.184 (CBR3 protein, human); EC 1.1.1.184 (DHRS4 protein, human)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  4 / 2182 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27770845
[Au] Autor:Bailey DG
[Ad] Endereço:Lawson Health Research Institute and Department of Medicine, Schulich School of Medicine & Dentistry, Western University, London, Ont, Canada.
[Ti] Título:Better to Avoid Grapefruit with Certain Statins.
[So] Source:Am J Med;129(11):e301, 2016 11.
[Is] ISSN:1555-7162
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Citrus paradisi
Inibidores de Hidroximetilglutaril-CoA Redutases
[Mh] Termos MeSH secundário: Bebidas
Estudos Cross-Over
Interações Alimento-Droga
Seres Humanos
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171129
[Lr] Data última revisão:
171129
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  5 / 2182 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28941798
[Au] Autor:Tang S; Chen A; Zhou X; Zeng L; Liu M; Wang X
[Ad] Endereço:Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
[Ti] Título:Assessment of the inhibition risk of shikonin on cytochrome P450 via cocktail inhibition assay.
[So] Source:Toxicol Lett;281:74-83, 2017 Nov 05.
[Is] ISSN:1879-3169
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Shikonin is a naphthoquinone pigment extracted from roots of Lithospermum erythrorhizon Sieb. et Zucc. (Boraginaceae), and possesses various pharmaceutical activities, such as anti-inflammation and anti-cancer effects. In addition, shikonin as a natural red colorant for food garnishment and cosmetics ingredient is widely used in the world. However, the inhibition risk of shikonin on cytochrome P450 (CYP) remains unclear. The aim of this study was to investigate the potential inhibition of shikonin against CYP1A2, CYP2B1/6, CYP2C9/11, CYP2D1/6, CYP2E1 and CYP3A2/4 activities in human and rat liver microsomes through cocktail approach in vitro. The results demonstrated that shikonin exhibited no time-dependent inhibition of CYP activities. In human liver microsomes, shikonin was not only a mixed inhibitor of CYP1A2, CYP2B6, CYP2C9, CYP2D6 and CYP3A4, but also a competitive inhibitor of CYP2E1, with K values no more than 7.72µM. In rat liver microsomes, shikonin also exhibited the mixed inhibition on CYP1A2, CYP2B1, CYP2C11, CYP2D1, and the competitive inhibition on CYP2E1. Interestingly, shikonin presented an atypical kinetic inhibition of CYP3A2-mediated midazolam 1-hydroxylation in rats. In conclusion, the relatively low K values of shikonin would have a high risk potential to cause the possible toxicity, especially drug-drug or food-drug interactions based on the potent inhibition of CYP enzymes.
[Mh] Termos MeSH primário: Inibidores das Enzimas do Citocromo P-450/toxicidade
Sistema Enzimático do Citocromo P-450/metabolismo
Microssomos Hepáticos/efeitos dos fármacos
Naftoquinonas/toxicidade
[Mh] Termos MeSH secundário: Animais
Sistema Enzimático do Citocromo P-450/genética
Interações Medicamentosas
Interações Alimento-Droga
Seres Humanos
Hidroxilação
Concentração Inibidora 50
Masculino
Microssomos Hepáticos/enzimologia
Ratos
Ratos Sprague-Dawley
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cytochrome P-450 Enzyme Inhibitors); 0 (Naphthoquinones); 3IK6592UBW (shikonin); 9035-51-2 (Cytochrome P-450 Enzyme System)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171106
[Lr] Data última revisão:
171106
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170925
[St] Status:MEDLINE


  6 / 2182 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28635328
[Au] Autor:Kampouraki E; Kamali F
[Ad] Endereço:a Institute of Cellular Medicine , Newcastle University , Newcastle upon Tyne , UK.
[Ti] Título:Dietary implications for patients receiving long-term oral anticoagulation therapy for treatment and prevention of thromboembolic disease.
[So] Source:Expert Rev Clin Pharmacol;10(8):789-797, 2017 Aug.
[Is] ISSN:1751-2441
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The effectiveness of oral anticoagulation therapy with warfarin (a vitamin K antagonist) in the treatment of thromboembolic disease, including stroke prophylaxis in patients with atrial fibrillation is well recognised. However, warfarin has a narrow therapeutic window and an unpredictable anticoagulation response, which make it difficult to achieve and maintain optimal anticoagulation. Various dietary factors, including sudden changes in eating patterns, can significantly alter anticoagulation control, thereby potentially exposing patients to the risk of bleeding or thromboembolic complications. Dietary vitamin K intake is a particularly important factor, given the mechanism of action of warfarin. Areas covered: In this article, we cover the sources of vitamin K and their potential effect of dietary vitamin K on anticoagulation response to warfarin. We also discuss the results of studies on the effect of vitamin K supplementation on anticoagulation stability. Expert commentary: A stable dietary vitamin K, promoted by daily oral vitamin K supplementation, can improve anticoagulation stability in patients on warfarin therapy. There is experimental evidence in animals that dietary vitamin K affects anticoagulation response to the direct thrombin inhibitor, ximelagatran. Whether dietary vitamin K affects anticoagulation response to the currently licensed direct oral anticoagulants (DOACs) in man remains to be investigated.
[Mh] Termos MeSH primário: Anticoagulantes/administração & dosagem
Tromboembolia/prevenção & controle
Vitamina K/administração & dosagem
Varfarina/administração & dosagem
[Mh] Termos MeSH secundário: Administração Oral
Animais
Anticoagulantes/efeitos adversos
Anticoagulantes/farmacologia
Fibrilação Atrial/complicações
Fibrilação Atrial/tratamento farmacológico
Azetidinas/administração & dosagem
Azetidinas/farmacologia
Benzilaminas/administração & dosagem
Benzilaminas/farmacologia
Dieta
Suplementos Nutricionais
Interações Alimento-Droga
Hemorragia/induzido quimicamente
Seres Humanos
Acidente Vascular Cerebral/etiologia
Acidente Vascular Cerebral/prevenção & controle
Tromboembolia/etiologia
Vitamina K/antagonistas & inibidores
Varfarina/efeitos adversos
Varfarina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticoagulants); 0 (Azetidines); 0 (Benzylamines); 12001-79-5 (Vitamin K); 49HFB70472 (ximelagatran); 5Q7ZVV76EI (Warfarin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170804
[Lr] Data última revisão:
170804
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170622
[St] Status:MEDLINE
[do] DOI:10.1080/17512433.2017.1345622


  7 / 2182 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28399577
[Au] Autor:Alpers DH; Young GP; Tran CD; Mortimer EK; Gopalsamy GL; Krebs NF; Manary MJ; Ramakrishna BS; Binder HJ; Brown IL; Miller LV
[Ad] Endereço:School of Medicine, Washington University, St Louis, Missouri, USA.
[Ti] Título:Drug-development concepts as guides for optimizing clinical trials of supplemental zinc for populations at risk of deficiency or diarrhea.
[So] Source:Nutr Rev;75(3):147-162, 2017 03 01.
[Is] ISSN:1753-4887
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Studies on the efficacy of zinc supplementation for treatment or prevention of diarrhea have shown an inconsistent effect in populations at risk for zinc deficiency. Unlike drugs, which have no preexisting presence in the body, endogenous zinc must be assessed pharmacokinetically by isotope tracer studies. Although such methods have produced much data, very few studies have estimated the dose and the timing of dosing of zinc supplementation. This review examines drug kinetics used to establish the best dose, the timing of such doses, and the mechanism of action through pharmacodynamic markers and applies them, where possible, to zinc supplements. The findings reveal that little is known, especially in children at highest risk of zinc deficiency. Key data missing to inform proper dosing, whether for treatment of disease or for preventive nutrient supplementation, are noted. Addressing these uncertainties could improve study design, leading to future studies of zinc supplements that might be of greater benefit.
[Mh] Termos MeSH primário: Diarreia/tratamento farmacológico
Suplementos Nutricionais
Zinco/administração & dosagem
Zinco/deficiência
[Mh] Termos MeSH secundário: Ensaios Clínicos como Assunto
Interações Medicamentosas
Interações Alimento-Droga
Seres Humanos
Política Nutricional
Fatores de Risco
Zinco/farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
J41CSQ7QDS (Zinc)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170412
[St] Status:MEDLINE
[do] DOI:10.1093/nutrit/nuw065


  8 / 2182 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28349328
[Au] Autor:Behm MO; Yee KL; Liu R; Levine V; Panebianco D; Fackler P
[Ad] Endereço:Merck & Co., Inc., Kenilworth, NJ, USA. martin_behm@merck.com.
[Ti] Título:The Effect of Food on Doravirine Bioavailability: Results from Two Pharmacokinetic Studies in Healthy Subjects.
[So] Source:Clin Drug Investig;37(6):571-579, 2017 Jun.
[Is] ISSN:1179-1918
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND OBJECTIVE: Doravirine is a novel non-nucleoside reverse transcriptase inhibitor being developed for the treatment of HIV-1. In two open-label, single-dose, randomized, two-period, crossover trials, the bioavailability of doravirine administered alone or in a fixed-dose combination (FDC) was determined under fed and fasted conditions. METHODS: Doravirine 100 mg alone or with lamivudine and tenofovir disoproxil fumarate (each 300 mg) were administered to healthy subjects fasted or 30 min after a high-fat, high-calorie breakfast. Twenty-eight subjects, aged 26-55 years, enrolled (doravirine, n = 14; FDC, n = 14). The sequence of fed/fasted treatment was randomized (1:1). Pharmacokinetic data were analyzed as geometric mean ratios (GMRs) with 90% confidence intervals. RESULTS: Doravirine area under the plasma concentration-time curve (AUC) from time zero to infinity (fed/fasted GMRs: alone 1.16 [1.06-1.26]; FDC 1.10 [1.02-1.20]), AUC from time zero to the last measurement (GMRs: alone 1.18 [1.08-1.29]; FDC 1.10 [1.01-1.20]), and plasma concentration 24 h after administration (GMRs: alone 1.36 [1.19-1.55]; FDC 1.26 [1.13-1.41]) values increased in the fed versus fasted state when administered alone or as the FDC; the magnitude was not clinically meaningful. Doravirine maximum achieved concentration was similar after fed or fasted administration for both doravirine alone and FDC (GMRs: alone 1.03 [0.89-1.19]; FDC 0.95 [0.80-1.12]). The pharmacokinetics of tenofovir and lamivudine in the FDC were also slightly altered by administration with food; the changes were not clinically meaningful. CONCLUSIONS: All treatments were generally well tolerated. Food had no clinically meaningful effect on doravirine 100 mg alone or as part of an FDC.
[Mh] Termos MeSH primário: Interações Alimento-Droga
Piridonas/farmacocinética
Inibidores da Transcriptase Reversa/farmacocinética
Triazóis/farmacocinética
[Mh] Termos MeSH secundário: Adulto
Área Sob a Curva
Disponibilidade Biológica
Estudos Cross-Over
Feminino
Seres Humanos
Masculino
Meia-Idade
Tenofovir/farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Pyridones); 0 (Reverse Transcriptase Inhibitors); 0 (Triazoles); 913P6LK81M (DORAVIRINE); 99YXE507IL (Tenofovir)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170329
[St] Status:MEDLINE
[do] DOI:10.1007/s40261-017-0512-5


  9 / 2182 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28339328
[Au] Autor:Landier W; Hageman L; Chen Y; Kornegay N; Evans WE; Bostrom BC; Casillas J; Dickens DS; Angiolillo AL; Lew G; Maloney KW; Mascarenhas L; Ritchey AK; Termuhlen AM; Carroll WL; Relling MV; Wong FL; Bhatia S
[Ad] Endereço:Wendy Landier, Lindsey Hageman, Yanjun Chen, and Smita Bhatia, University of Alabama at Birmingham, Birmingham, AL; Nancy Kornegay, William E. Evans, and Mary V. Relling, St. Jude Children's Research Hospital, Memphis, TN; Bruce C. Bostrom, Children's Hospitals and Clinics of Minnesota, Minneapolis,
[Ti] Título:Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1.
[So] Source:J Clin Oncol;35(15):1730-1736, 2017 May 20.
[Is] ISSN:1527-7755
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose Children with acute lymphoblastic leukemia (ALL) are generally instructed to take mercaptopurine (6-MP) in the evening and without food or dairy products. This study examines the association between 6-MP ingestion habits and 6-MP adherence, red cell thioguanine nucleotide (TGN) levels, and risk of relapse in children with TMPT wild-type genotype. Methods Participants included 441 children with ALL receiving oral 6-MP for maintenance. Adherence was monitored over 48,086 patient-days using the Medication Event Monitoring System; nonadherence was defined as adherence rate < 95%. 6-MP ingestion habits examined included: takes 6-MP with versus never with food, takes 6-MP with versus never with dairy, and takes 6-MP in the evening versus morning versus varying times. Results Median age at study was 6 years (range, 2 to 20 years); 43.8% were nonadherent. Certain 6-MP ingestion habits were associated with nonadherence (taking 6-MP with dairy [odds ratio (OR), 1.9; 95% CI, 1.3 to 2.9; P = .003] and at varying times [OR, 3.4; 95% CI, 1.8 to 6.3; P = .0001]). After adjusting for adherence and other prognosticators, there was no association between 6-MP ingestion habits and relapse risk (6-MP with food: hazard ratio [HR], 0.7; 95% CI, 0.3 to 1.9; P = .5; with dairy: HR, 0.3; 95% CI, 0.07 to 1.5; P = .2; taken in evening/night: HR, 1.1; 95% CI, 0.2 to 7.8; P = .9; at varying times: HR, 0.3; 95% CI, 0.04 to 2.7; P = .3). Among adherent patients, there was no association between red cell TGN levels and taking 6-MP with food versus without (206.1 ± 107.1 v 220.6 ± 121.6; P = .5), with dairy versus without (220.1 ± 87.8 v 216.3 ± 121.3; P =.7), or in the evening/night versus morning/midday versus varying times (218.8 ± 119.7 v 195.5 ± 82.3 v 174.8 ± 93.4; P = .6). Conclusion Commonly practiced restrictions surrounding 6-MP ingestion might not influence outcome but may hinder adherence. Future recommendations regarding 6-MP intake during maintenance therapy for childhood ALL should aim to simplify administration.
[Mh] Termos MeSH primário: Antimetabólitos Antineoplásicos/administração & dosagem
Adesão à Medicação
Mercaptopurina/administração & dosagem
Leucemia-Linfoma Linfoblástico de Células Precursoras/sangue
Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico
Tioguanina/sangue
Tionucleotídeos/sangue
[Mh] Termos MeSH secundário: Administração Oral
Adolescente
Adulto
Criança
Pré-Escolar
Laticínios
Esquema de Medicação
Monitoramento de Medicamentos/métodos
Eritrócitos/metabolismo
Feminino
Interações Alimento-Droga
Seres Humanos
Masculino
Metiltransferases/genética
Metiltransferases/metabolismo
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antimetabolites, Antineoplastic); 0 (Thionucleotides); E7WED276I5 (Mercaptopurine); EC 2.1.1.- (Methyltransferases); EC 2.1.1.67 (thiopurine methyltransferase); FTK8U1GZNX (Thioguanine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170325
[St] Status:MEDLINE
[do] DOI:10.1200/JCO.2016.71.7579


  10 / 2182 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28247011
[Au] Autor:Mittapalli RK; Nuthalapati S; Shepherd SP; Xiong H
[Ad] Endereço:Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., 1N Waukegan Road, AP31-3, North Chicago, IL, 60064, USA. rajendar.mittapalli@abbvie.com.
[Ti] Título:Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.
[So] Source:Cancer Chemother Pharmacol;79(3):587-594, 2017 Mar.
[Is] ISSN:1432-0843
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The objective of the manuscript is to describe the development of a population pharmacokinetic model for ABT-767, a potent and orally bioavailable inhibitor of poly (ADP-ribose) polymerase enzyme, and to evaluate the potential influence of patient demographics and baseline covariates on the pharmacokinetics of ABT-767. METHODS: A total of 1809 plasma ABT-767 concentrations from 90 subjects were used for population pharmacokinetic modeling. Covariates screened for influence on pharmacokinetic parameters were body weight, lean body weight, body surface area, albumin, creatinine clearance, serum creatinine, liver function tests, and age. The effect of food on absorption and bioavailability were also evaluated. Model validation was performed using bootstrap analysis and visual predictive check. RESULTS: A two-compartment model with firstorder absorption adequately described the pharmacokinetics of ABT-767. The population estimates of apparent clearance from central compartment (CL/F), volume of central compartment (V /F), and absorption rate constant (k ) were 7.34 L/h, 25.8 L, 1.45 h , respectively. The estimates of interindividual variabilities (%CV) in CL/F, V /F, and k were 40.4, 40.5, and 53.8%, respectively. The k was influenced by food. Albumin on CL/F was a statistically significant covariate; however, it explained only 8% of the variability in the pharmacokinetics of ABT-767. CONCLUSIONS: Albumin on CL/F was the only statistically significant baseline covariate affecting ABT-767 pharmacokinetics, but it only explained a fraction of the pharmacokinetic variability. Dosage adjustments based on body size, age, or mild renal impairment are not needed for ABT-767. The developed model will be used to evaluate ABT-767 exposure-response analyses and to perform simulations for different dose and dosing regimens.
[Mh] Termos MeSH primário: Proteína BRCA1/genética
Proteína BRCA2/genética
Benzamidas/farmacocinética
Neoplasias das Tubas Uterinas/tratamento farmacológico
Neoplasias das Tubas Uterinas/genética
Neoplasias/tratamento farmacológico
Neoplasias/genética
Neoplasias Ovarianas/tratamento farmacológico
Neoplasias Ovarianas/genética
Neoplasias Peritoneais/tratamento farmacológico
Neoplasias Peritoneais/genética
Inibidores de Poli(ADP-Ribose) Polimerases/farmacocinética
Sulfonamidas/farmacocinética
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Albuminas/metabolismo
Benzamidas/administração & dosagem
Benzamidas/uso terapêutico
Disponibilidade Biológica
Peso Corporal
Feminino
Interações Alimento-Droga
Heterozigoto
Seres Humanos
Absorção Intestinal
Masculino
Meia-Idade
Modelos Biológicos
Mutação
População
Sulfonamidas/administração & dosagem
Sulfonamidas/uso terapêutico
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ABT-767); 0 (Albumins); 0 (BRCA1 Protein); 0 (BRCA1 protein, human); 0 (BRCA2 Protein); 0 (BRCA2 protein, human); 0 (Benzamides); 0 (Poly(ADP-ribose) Polymerase Inhibitors); 0 (Sulfonamides)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170613
[Lr] Data última revisão:
170613
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170302
[St] Status:MEDLINE
[do] DOI:10.1007/s00280-017-3262-4



página 1 de 219 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde